Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ornithine SCHEMBL3801712 | 0.85 | GSR (0.36) | GSRSLC7A5ARG1CPB2RAB9A | |
| Ornithine SCHEMBL9998922 | 0.78 | MEN1 (0.38) | GSR | |
| SCHEMBL2429665 | 0.78 | NPC1 (0.45) | NPC1RAB9A | |
| Ornithine SCHEMBL9998924 | 0.74 | GSR (0.38) | GSRSLC7A5ARG1CPB2CPB1 | |
| Lysine SCHEMBL28155084 | 0.73 | GSR (0.56) | GSRGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL4636002 | 0.72 | NPC1 (0.40) | NPC1RAB9A | |
| SCHEMBL28044670 | 0.71 | GSR (0.43) | GSRGRIA1GRIA2GRIA3GRIA4 | |
| Lysine SCHEMBL28681105 | 0.69 | GSR (0.54) | GSRGRIA1GRIA2GRIA3GRIA4 | |
| Lysine SCHEMBL31606629 | 0.69 | GSR (0.54) | GSRGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL9139120 | 0.69 | NPC1 (0.42) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312877-A1 | ENGINEERED TUNABLE NANOPARTICLES FOR DELIVERY OF THERAPEUTICS, DIAGNOSTICS, AND EXPERIMENTAL COMPOUNDS AND RELATED COMPOSITIONS FOR THERAPEUTIC USE | APARNA BIOSCEIENCES (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2257280-A1 | ENGINEERED TUNABLE NANOPARTICLES FOR DELIVERY OF THERAPEUTICS, DIAGNOSTICS, AND EXPERIMENTAL COMPOUNDS AND RELATED COMPOSITIONS FOR THERAPEUTIC USE | Aparna Biosciences (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009108822-A1 | ENGINEERED TUNABLE NANOPARTICLES FOR DELIVERY OF THERAPEUTICS, DIAGNOSTICS, AND EXPERIMENTAL COMPOUNDS AND RELATED COMPOSITIONS FOR THERAPEUTIC USE | APARNA BIOSCIENCES (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312877-A1 | ENGINEERED TUNABLE NANOPARTICLES FOR DELIVERY OF THERAPEUTICS, DIAGNOSTICS, AND EXPERIMENTAL COMPOUNDS AND RELATED COMPOSITIONS FOR THERAPEUTIC USE | TLR3, CHIA, TSG101 | GSR 2747/4885SLC7A5 3132/4885GRIA1 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.